Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Drug Industry Warned Of Impending Deficiency Letters For Pre-Filled Syringes

This article was originally published in The Gold Sheet

Executive Summary

An official with the generic drug industry warned of a potential onslaught of ANDA deficiency letters going to manufacturers of generic drugs combined with needleless pre-filled glass syringes and connecting devices for not adhering to FDA guidance. FDA is now requiring more data to ensure the safety of these products, including human factors testing and performance testing.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS000998

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel